Stay updated on Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Sign up to get notified when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.

Latest updates to the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page
- Check6 days agoChange DetectedAdded a Locations section with California sites for this study. Page revision updated to v3.3.3.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the page. This is a version update and does not modify the study details or other user-facing content.SummaryDifference0.1%

- Check42 days agoChange DetectedAdministrative date-stamp updates have been added (Results First Posted [Estimated], Certification/Extension First Posted [Estimated], Last Update Posted [Estimated]), and a funding-status notice has been removed. These changes do not affect the study details, eligibility, or results.SummaryDifference0.7%

- Check49 days agoChange DetectedAdded final results for NCT03160079, including ORR (CR+CRh), MRD negativity, 2-year relapse-free survival, and 2-year overall survival, and updated the study status to Completed with results posted. Included investigator and location details and referenced study documents.SummaryDifference2%

- Check63 days agoChange DetectedThe page appears unchanged between the two screenshots; no notable updates to study details or eligibility criteria are evident.SummaryDifference0.4%

- Check85 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference3%

Stay in the know with updates to Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.